Melanomas arising in the uveal tract of the eye are a rare form of the disease with a biology
and clinical phenotype distinct from their more common cutaneous counterparts. Treatment …

Abstract Treatment of primary intraocular uveal melanoma has developed considerably, its
driver genes are largely unraveled, and the ways to assess its risk for metastases are very …

Background Tebentafusp, a T-cell receptor–bispecific molecule that targets glycoprotein 100
and CD3, is approved for adult patients who are positive for HLA-A* 02: 01 and have …

Background Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a
low tumor mutational burden and a 1-year overall survival of approximately 50% in patients …

In patients with previously treated metastatic uveal melanoma, the historical 1 year overall
survival rate is 37% with a median overall survival of 7.8 months. We conducted a …

PURPOSE Metastatic uveal melanoma has poor overall survival (OS) and no approved
systemic therapy options. Studies of single-agent immunotherapy regimens have shown …

PURPOSE This study aimed to assess the efficacy of the combination of nivolumab (nivo)
plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) …

Purpose: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a
melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain …

Background Combined immune checkpoint blockade (ICB) provides unprecedented efficacy
gains in numerous cancer indications, with PD-1 inhibitor nivolumab plus CTLA-4 inhibitor …

Uveal melanoma (UM) represents the most prominent primary eye cancer in adults. With an
incidence of approximately 5 cases per million individuals annually in the United States, UM …